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Sunﬂower Trypsin Inhibitor (SFTI-1) analogues have been prepared from simple linear precursors pro-
duced either by chemical synthesis or following puriﬁcation from Escherichia coli. We have shown, for the
ﬁrst time that these linear SFTI-1 derived peptide sequences can be converted to circular peptides via
selective consecutive acyl transfer reactions, and that the products derived from synthetic and bacterial
origin are identical. Preliminary analysis of the semi-synthetic SFTI-1 analogues conﬁrmed SFTI-I10H as
an inhibitor of Kallikrein-5 (KLK5) protease that could also mediate its action on human keratinocytes.
The preliminary results obtained serve as a useful starting point for the biological production of SFTI-1
based, selective KLK5 inhibitors for the treatment of atopic dermatitis.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
Proteases are a diverse, ubiquitous class of enzymes that per-
form vital roles in a myriad of biological processes, such as apo-
ptosis, blood coagulation and pathogenesis.1 Protease inhibitors are
key regulators of such processes, and therefore are extremely im-
portant pharmacological candidates. A number of therapeutic
protease inhibitors are already available for clinical use, combating
HIV/AIDS, cancer and hypertension, whilst proteases were recently
estimated to represent 5e10% of current pharmaceutical targets.1,2
This demonstrates a requirement for identiﬁcation and de-
velopment of new protease inhibitors.
The BowmaneBirk protein family is a group of approximately 50
serine protease inhibitors, found primarily in the seeds of plant
species, where they are involved in protection of the host against
pests and pathogens.3 BowmaneBirk inhibitors (BBIs) typically
comprise 60e90 amino acids, and perform dual inhibition of
trypsin- and/or chymotrypsin-like proteases via disulﬁde-bonded
b-hairpin loop motifs, which bind at catalytic sites via canonical
protease recognition sequences.4,5 In the early 1990s it was dem-
onstrated that synthetic peptide mimics of the BBI b-hairpin loop
motif retain biological activity.5,6 Subsequently a naturally--mail address: d.macmillan@
r Ltd. This is an open access articloccurring b-hairpin peptide with broad inhibitory activity to-
wards serine proteases was isolated from Helianthus annus sun-
ﬂower seeds.7 Sunﬂower trypsin inhibitor-1 (SFTI-1) contains just
14 amino acids, including a disulﬁde bond and a contiguous circular
peptide backbone. These features are not uncommon in small an-
timicrobial peptides,8 conferring high rigidity and, consequently,
potent activity; SFTI-1 is a signiﬁcantly more potent inhibitor of
bovine b-trypsin than BBI’s and synthetic analogues.7 Due to its
size, stability and activity towards a range of proteases, SFTI-1 is an
attractive therapeutic drug candidate, and has emerged recently as
a useful framework for peptide ‘grafting’.9 Mutation of selected
SFTI-1 residues has improved selectivity towards certain sub-
strates.10,11 whilst insertion of bioactive peptide sequences into this
circular scaffold has been shown to improve their in vivo stability.12
SFTI-1 is known to act upon a range of serine proteases, in-
cluding cathepsin G7, matriptase,13 and kallikrein-related pepti-
dases (KLKs),14 a group of ﬁfteen related human proteases with
roles in a variety of physiological processes and strong links to
cancer progression.15,16 Swedberg and co-workers recently ob-
served inhibition of KLK4, a promising target for prostate cancer
treatment, by SFTI-1.14 They produced a sequence variant (where
RCTK was modiﬁed to FCQR) with increased potency and improved
selectivity over other proteases. Of the various proteases tested, the
closely-related KLK5, itself implicated in prostate cancer pro-
gression17 and skin conditions such as rosacea and atopic derma-
titis,18,19 exhibited comparatively weak inhibition by thee under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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the SFTI-1 framework as an inhibitor of KLK5. We have therefore
sought to clarify the inhibitory activity of SFTI-1 derived peptides
towards KLK5 (Fig. 1), with a view to studying its role in skin barrier
homeostasis and developing selective therapeutic agents for the
treatment atopic dermatitis.Fig. 1. Overlay of the SFTI-1/Trypsin complex (PDB ID: 1SFI) and KLK5 (PDB ID: 2PSX)
emphasises the similarity between the structures around the SFTI-1 (magenta) binding
site.
Fig. 2. Semi-synthesis of SFTI-1 analogues. (a) SFTI-1 Pro-peptide sequence with SFTI-
1 shown in red. (b) Redesigned SFTI-1 derived sequence to enable cyclisation via N/S
acyl transfer. (c) General reaction scheme for production of SFTI-1 analogues.Numerous strategies are available for circular peptide pro-
duction, involving both chemical20e22 and biological23 methods.
We have recently demonstrated that circular peptides can be pre-
pared in one-pot from a linear precursor adorned simply with a C-
terminal Xaa-Cys motif (where Xaa preferably denotes Cys/His/
Gly), which undergoes N/S acyl shift, and an N-terminal Cys,
which intercepts a transient C-terminal thioester.24 The peptide is
ultimately cyclised via a native chemical ligation-type process.25
Although several N/S acyl transfer methods have been re-
ported,26 this reaction can be routinely applied to linear peptides of
synthetic or recombinant origin, with the requirement for only
native amino acids facilitating bacterial protein expression, pro-
viding an alternative route to intein-mediated splicing strategies.27
Here, we have utilised this strategy for the ﬁrst time to produce
both synthetic and recombinant analogues of SFTI-1, and demon-
strated that the peptide is an inhibitor of KLK5 action on human
keratinocytes in cell culture.2. Results and discussion
Wild-type SFTI-1 is expressed as a fusion protein, embedded
within seed storage albumin precursors (Fig. 2a), which are pro-
cessed by an asparaginyl endopeptidase to cyclise the excised se-
quence.28 For our purposes, in order to suitably position an Xaa-Cys
motif at the C-terminus, the sequence was redesigned such that
thioester formation could take place at this site (Fig. 2b, c). Neither
of the native Arg-Cys nor Ile-Cys motifs were ideal for thioester
synthesis via our N/S acyl transfer method and so Ile10 was ini-
tially substituted for glycine in model experiments (I10G). This
substitution had previously been shown to give rise to a folded
SFTI-1 analogue.10 The linear SFTI-I10G precursor (Fig. 2b) could be
readily prepared by automated solid phase peptide synthesis (SPPS)
and by puriﬁcation from E. coli as a fusion with thioredoxin. While
solid phase synthesis of short circular peptides such as SFTI-
analogues and cyclotides can be routinely achieved through total
synthesis, the availability of a straightforward recombinantbiological method renders thousands of analogues of these species
available through straightforward DNA engineering. Biological
production of the linear precursor also negates the need for
wasteful use of organic solvents, excess building blocks, coupling
reagents, protecting groups and proprietary linkers or solid
supports.
Additionally our semi-synthetic method complements the few
existingmethods for the biological production of head-to-tail cyclic
peptides such as intein- or sortase-mediated protein cyclisation
and offers some advantages in that the expressed fusion protein
need not be soluble or folded in order to be processed into cyclic
product.
Synthetic SFTI-I10G was ﬁrst prepared using Fmoc SPPS in au-
tomated fashion on commercially available Fmoc-Cys(Trt)-
NovaSyn-TGT resin. After cleavage from the resin (95% v/v tri-
ﬂuoroacetic acid: 2.5% v/v H2O: 2.5% v/v 1,2-ethanedithiol) and
HPLC puriﬁcation the peptide was cyclised under typical reaction
conditions.24,27 This involved heating the sample, at an approxi-
mate concentration of 1 mg ml1 (0.5e1 mM) in 0.1 M sodium
phosphate buffer; pH 5.8, to 55 C in the presence of 10% w/v
(0.7 M) sodium 2-mercaptoethane sulfonate (MESNa) for 48 h.
After this time the cyclic peptide was recovered in 46% yield. In
order to oxidise the resulting dithiol to the disulﬁde the peptide
was stirred overnight in 0.1 M NaHCO3 (pH 8.0) and the SFTI-1
analogue was then obtained after HPLC-puriﬁcation.
For bacterial production of SFTI-I10G the E. Coli codon optimised
DNA sequence, corresponding to the peptide shown in Fig. 2b, was
purchased and cloned into expression vector pET 32a. The fusion
was designed such that the desired linear precursor sequence
would be expressed as an N-terminal fusion with His6-tagged thi-
oredoxin, and released from the fusion protein following in-
cubationwith Tobacco Etch Virus (TEV) protease. Consequently the
N-terminal Cys residue was preceded by the sequence ENLYFQ. The
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obtained from the soluble fraction of the cell-free extract, following
Ni2þ afﬁnity chromatography (Fig. 3a). 70 mg of the fusion protein
could be routinely isolated from 1 L of cell culture. Fractions con-
taining the fusion protein were pooled and dialysed against 50 mM
TriseHCl; pH 8 buffer containing 100 mM NaCl, 1 mM DTT and
0.5 mM EDTA prior to incubation with TEV protease (0.1 mg ml1).
Exposure of the precursor to TEV protease resulted in almost
complete liberation of the linear peptide in 4 h (Fig. 3b), which was
subsequently isolated by preparative reverse-phase HPLC. Recovery
of w3 mg of linear peptide per litre of cell culture was routinely
achieved in this un-optimised process.Fig. 3. (a) Puriﬁcation of Trx-SFTI-I10G fusion protein. Lane M¼molecular weight markers, lane 1¼cell free extract (soluble fraction), lane 2¼column ﬂow-through, lanes
3e4¼5e20 mM imidazole wash, lanes 5e7 40e250 mM imidazole elution. (b) TEV protease mediated cleavage of SFTI linear precursor from Trx. The SFTI peptide is too small to be
visualised on the gel. (c) ESI-MS analysis of the HPLC puriﬁed linear precursor (upper panel), cyclised product (middle panel) and cyclised and oxidised SFTI analogue (bottom
panel).
Fig. 4. 1H NMR analysis of the amide region of (a) SFTI-I10G, and (b) SFTI-I10H
analogues.With the linear precursor in hand (Fig. 3c upper panel), the
backbone was cyclised in a similar manner to that described above
for the synthetic peptide (see experimental details for further in-
formation). The reaction was monitored by LCeMS, which clearly
showed consumption of the starting material over a 48 h period at
45 C. The circular product (Fig. 3c, middle panel) was isolated by
preparative HPLC and oxidised by stirring the sample in ammo-
nium carbonate buffer overnight (Fig. 2c, lower panel). Both the
synthetic and biological methods gave rise to sufﬁcient quantities
for examination of the structure and bioactivity. E. coli produced
approximately 250 mg of folded and oxidised peptide per litre of cell
culture, which is comparable with intein-mediated methods.29
Although preliminary LC and MS analyses showed successful
SFTI-I10G analogue synthesis we were concerned by the overly
complex 1H NMR spectrum for the I10G analogue (Fig. 4a). While
the signals corresponding to the folded peptide could be clearly
observed through examination of the 1He1H COSY, TOCSY, and
NOESY spectra (see Supplementary data) there was clear evidence
that this analogue existed in more than one signiﬁcantly populated
conformation. We presumed that removal of the side-chain of the
native Ile10 residue in our I10G analogue was key to the increased
conformational ﬂexibility and so we prepared an I10H analogue
(very amenable to N/S acyl shift), to restore the steric bulk of the
side-chain. Recombinant SFTI-I10H was prepared by site directed
mutagenesis of the I10G template and both the recombinant and
synthetic SFTI-I10H analogues were produced in an identical
manner to their I10G counterparts, with near identical yields for
each step. However, and in stark contrast to SFTI-I10G, SFTI-I10H
gave rise to a simpler 1H NMR spectrum with sharp, well deﬁned
signals (Fig. 4b) suggesting the existence of a single preferred
conformation in the folded structure.Furthermore, 1H NMR analysis of synthetic and recombinant
SFTI-I10H analogues, recorded at the same pH, (pH 4.5, Fig. 5a)
conﬁrmed that both samples were identical. Comparison of the CH-
a protons, commonly used to conﬁrm the folded state of analogues,
also showed that the I10H analogue was folded similarly to native
SFTI-1 (Fig. 5b).9 This data was extremely encouraging and so we
set out to conﬁrm that these analogues would serve as inhibitors of
commercially available KLK5.
First, we optimised a ﬂuorescence-based assay for KLK5 activity
employing commercially available KLK5 substrate Boc-Val-Pro-
Arg-AMC (Sigma). From the assay we established a Km value of
0.45 mM for this substrate, which was in good agreement with the
Fig. 5. (a) 1H NMR analysis of the amide region of the synthetic (upper spectrum) and
bacterially-derived (lower spectrum) SFTI-I10H analogues. (b) Comparison of CH-
a proton chemical shifts for WT,10 synthetic and recombinant I10G, and I10H
analogues.
Fig. 6. Exposure of cultured human keratinocytes to recombinant KLK5 (100 ng) in the
presence of (a) increasing SFTI-I10G and (b) SFTI-I10H analogues results in decreased
Ca2þ inﬂux.
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and the 7-amido-4-methylcoumarin (AMC) substrate with in-
creasing concentrations of SFTI analogues allowed preliminary IC50
data to be obtained (Table 1). As expected both analogues were
found to inhibit KLK5 and the I10H analogue proved to be more
than 100 times more active than the initial I10G analogue. An ad-
ditional I10G analogue, where the Pro-Arg motif from the Boc-Val-Table 1
KLK5 IC50 values for SFTI analogues
Entry Peptide IC50/mM
1 SFTI-I10G 15.7
2 SFTI-I10G grafta 12.3
3 SFTI-I10H 0.14
a SFTI-I10G where CTK is replaced with sequence CPR.Pro-Arg-AMC substrate substituted residues Thr-4 and Lys-5, was
also prepared but showed little advantage in terms of inhibitory
activity relative to the native sequence.
To further examine the KLK5 inhibitory activity of these SFTI
analogues, a cell culture assay was performed. This assay relied on
the known activation of protease activated receptor-2 (PAR-2),
present on the surface of normal human keratinocytes, by KLK5.
Proteolysis of PAR-2 by KLK5 results in exposure of a tethered li-
gand, which activates the receptor, triggering a pro-inﬂammatory
intracellular G-protein-coupled pathway.18 This process can be
observed by measuring the temporary Ca2þ inﬂux increase, which
occurs as a result of PAR-2 activation by KLK5. The assay was per-
formed by incubating the cells with KLK5 and increasing concen-
trations of SFTI analogue. The results (Fig. 6) showed that activation
of PAR-2 was completely suppressed by 50 mM SFTI-I10G or 25 mM
SFTI-I10H.3. Conclusion
In this study we have shown that Sunﬂower Trypsin Inhibitor
(SFTI-1) analogues are readily available through either synthetic or
biological means, from simple linear precursors, by N/S acyl
transfer followed by spontaneous cyclisation through native
chemical ligation. The cyclic synthetic and bacterially derived
products are identical. 1H NMR analysis also conﬁrmed that, in
contrast to the I10G analogue, SFTI-I10H adopts a single preferred
conformation, perhaps emphasising the importance of the steric
bulk associated with the side chain of this residue. While chemical
synthesis offers advantages of simple incorporation of various
amino acid analogues, the biological approach is easily scaled, less
wasteful, ideal for library production through mutagenesis, and
only requires water as solvent. Perhaps unsurprisingly (Fig. 1) both
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I10H was determined to have an IC50 of 0.14 mM and the increased
activity of SFTI-I10H over I10G was conﬁrmed in human keratino-
cytes. The results serve as a useful starting point for the de-
velopment of more potent and selective KLK5 inhibitory peptides,
based on the SFTI scaffold.
4. Experimental section
4.1. General experimental details
Reversed-phase high performance liquid chromatography (RP-
HPLC) was performed using a Dionex Ultimate 3000 system
equipped with a Phenomenex Jupiter 10m Proteo 90A, C12,
25021.2 mm column. Separations involved a mobile phase of 0.1%
TFA (v/v) in water (solvent A)/acetonitrile (solvent B) over a 5e60%
acetonitrile gradient. Analytical LC-MS was performed using a Wa-
ters Acquity UPLC SQD instrument equipped with an Acquity UPLC
BEH, C18, 2.1 x 50 mm column. Separations involved a mobile phase
of 0.1% formic acid (v/v) inwater (solvent A)/acetonitrile (solvent B)
over a 5e95% acetonitrile gradient. For SDS-PAGE samples were
denatured via addition to an equal volume of 2 Laemmli loading
buffer (containing 10 mM DTT) and incubation at 95 C for 2 min.
Samples were loaded onto 14% bis-Tris polyacrylamide gels,
alongside Mark12molecular weight marker (Invitrogen). Gels were
run at 175 V using Novex XCell Sure-Lock apparatus (Invitrogen)
and stained using Instant Blue (Triple Red).
4.2. Automated peptide synthesis
Automated solid-phase peptide synthesis (SPPS) was carried out
on an ABI 433A automated synthesiser using standard Fmoc amino
acids on a 0.05 mmol scale, and employing pre-loaded Fmoc-
Cys(Trt)-NovaSynTGT resin (loading¼0.19 mmol g1). Cleavage of
the assembled peptide chain was carried out in TFA (95% v/v)/1,2-
ethanedithiol (2.5%)/H2O(2.5%) for 4.5 h before ﬁltration and two
cycles of precipitation into cold ether followed by centrifugation
(4000 rpm, 4 C, 15 min). Preparative RP-HPLC was performed with
acetonitrile (0.1% v/v TFA) on a gradient of 5/60% (over 51 min,
7 mL min1) and monitored at wavelengths 230 nm, 254 nm, and
280 nm.
4.3. Peptide cyclisation and oxidation
Linear precursors to SFTI-I10X analogues (where X¼G or H)
were assembled and puriﬁed as described above. HPLC fractions
containing the desired peptide were identiﬁed by LCeMS and
lyophilised. Backbone cyclisation was then carried out in sodium
phosphate buffer (pH 5.8, 0.1 M) containing peptide (1 mg mL1),
sodium 2-mercaptoethane sulfonate (10% w/v) and sodium ascor-
bate (0.5% w/v). The samples were heated at 55 C in an Eppendorf
thermomixer with agitation (600 rpm) for 24 h. HPLC puriﬁcation,
as described above, yielded white powdered solids in 25e50%
isolated yields. Finally, stirring of the cyclic peptides (0.1 mg mL1)
in 0.1 M ammonium bicarbonate solution (pH 8.0) at room tem-
perature for 24 h yielded the disulﬁde-bonded structures. The re-
action mixture was lyophilised, dissolved in the minimum volume
of water and puriﬁed by RP-HPLC. Fractions containing the oxidised
peptidewere identiﬁed by LCeMS, pooled, and lyophilised to afford
the target products in 80e100% yields.
4.4. Production of recombinant SFTI-1 analogues
The DNA sequence, codon optimised for E. coli expression,
encoding the desired SFTI-I10G sequence preceded by
cysteine-terminated TEV protease recognition site(ENLYFQCFPDGRCTKSIPPGC-Stop), cloned into pUC57 vector, was
purchased from Genscript. Flanking sequences 50ggtattgagggtcgc
(upstream) and 50ggctctaactctcctct (downstream) were in-
corporated to facilitate PCR ampliﬁcation of the target insert, and
cloning into the pET32 Xa/LIC vector (Invitrogen), according to
manufacturers’ instructions.
Thioredoxin(Trx)-SFTI fusion protein was expressed in E. coli
BL21 (DE3) cells, via IPTG induction (1 mM ﬁnal concentration) at
O.D600 w0.6 followed by incubation at 30 C for 3 h. Cells were
harvested by centrifugation, resuspended in lysis buffer (20 mM
TriseHCl pH 7.9, 500 mM NaCl, 5 mM imidazole) supplemented
with a complete protease inhibitor cocktail tablet (Roche) and
1 mM PMSF, before lysis via sonication for a net time period of
2 min. Soluble Trx-SFTI was puriﬁed by immobilised metal-ion
chromatography (IMAC), analysed via SDS-PAGE, using Ni-IDA
resin (Generon), with washing and elution steps carried out using
lysis buffer containing 30 mM and 200 mM imidazole, respectively.
Eluted protein was dialysed overnight against 4 L TEV protease
reaction buffer (50 mM TriseHCl pH 8, 100 mM NaCl), and sup-
plemented with DTT (1 mM) and EDTA (0.5 mM) before proteolysis
by TEV protease (supplied by Dr Rachel Morgan, UCL) over four
hours at 30 C. The cleavage reaction was monitored by SDS-PAGE
and LCeMS. Liberated linear SFTI peptidewas puriﬁed via reversed-
phase HPLC. Fractions containing the linear peptide were identiﬁed
by LCeMS, pooled, and lyophilised.
A DNA expression construct encoding SFTI-I10H was created via
site-directed mutagenesis, using SFTI-I10G–pET32 Xa/LIC as
a template, primers 50accaaaagcattccgccgcattgctaaggctctaactc (for-
ward) and 50agttagagccttagcaatgcggcggaatgcttttggt (reverse), and
a QuikChange II kit (Agilent) according to manufacturer’s in-
structions. Protein expression, puriﬁcation and proteolysis were
carried out as described for SFTI-I10G.
4.5. Recombinant peptide cyclisation and folding
Backbone cyclisation reactions were carried out in a similar
manner as for the synthetic samples. Brieﬂy, lyophilised linear SFTI
precursor peptides were dissolved in 0.1 M sodium phosphate pH
5.8 (1 mg/ml ﬁnal concentration), containing MESNa (10% w/v) and
TCEP (0.5% w/v) or sodium ascorbate (0.5% w/v). Reactions were
agitated at 45 C for 48 h, monitored via LCeMS, followed by pu-
riﬁcation via RP-HPLC. Oxidative folding was carried out via dis-
solution of peptides in 0.1 M ammonium bicarbonate pH 8.5
(0.1 mg/ml ﬁnal concentration) followed by gentle stirring at room
temperate for 24 h. Successful oxidation was veriﬁed via LCeMS,
before puriﬁcation of peptides via RP-HPLC.
4.6. NMR spectroscopy
NMR samples were constituted in 20 mM NaHPO4 pH 4.5 sup-
plemented with 10% D2O. 1H, 1He1H COSY, 1He1H TOCSY and
1He1H NOESY spectra were acquired at 25 C using 500 MHz,
600 MHz and 700 MHz Bruker Avance III spectrometers.
4.7. Protease inhibition assays
KLK 5 (0.5 mgmL1, 0.63 mL) was incubated for 3 min in reaction
buffer: 50 mM TriseHCl (pH 8.0) containing 20 mM CaCl2 before
addition of various concentrations of SFTI analogue
(0.5 nMe66.2 mM). Following further incubation (2 min), addition
of ﬂuorogenic Boc-VPR-AMC (79 mM,1.00 mL) initiated the reaction,
which was followed for 5 min on a Carey Eclipse ﬂuorimeter
(Agilent) set at excitation¼380 nm and emission¼460 nm. Blanks
were performed without enzyme or inhibitor and controls without
inhibitor. All reactions were performed in triplicate in a ﬁnal re-
action volume of approximately 150 mL.
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Measurement of intracellular Ca2þ ﬂuxwas performed using the
FluoForte Calcium Assay kit (Enzo Life Sciences). Human kerati-
nocytes were plated in growth medium in 96-well plates at
1104 cells/100 mL well. After 24 h, the growth medium was re-
moved, and 100 mL of Dye-loading solution was added. The cells
were further incubated for 45 min at 37 C and 15 min at room
temperature before stimulation, and during the incubation, 100 ng
of recombinant human KLK5 was incubated with SFTI analogues at
37 C for 10 min, after which the cells were challenged with the
mixture of recombinant human KLK5 and SFTI analogue, and
a timeeresponse curve of intracellular [Ca2þ] signal was recorded
via real-time monitoring of ﬂuorescence intensity at
excitation¼485 nm and emission¼520 nm in a Microplate Reader
(FLUOstar OPTIMA).
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